Europe approves Opdivo-Yervoy immuno combination for melanoma

May 12, 2016 News BioVox

Bristol-Myers Squibb Co. (NYSE:BMY) said the European Commission approved Opdivo nivolumab in combination with Yervoy ipilimumab to treat advanced melanoma in adults independent of BRAF mutation status. The company said it is the first combination of two immuno-oncology therapies to be approved in the EU.

BMS markets both drugs. Opdivo, a human IgG4 against PD-1, is approved in the EU as monotherapy to treat locally advanced melanoma, and to treat advanced or metastatic squamous non-small cell lung cancer (NSCLC). Yervoy, a human mAb against CTLA-4 (CD152), is also approved as monotherapy in the EU to treat advanced melanoma.


BioVox
BioVox

With a local focus and global reach, BioVox shares insights into the Belgian life sciences ecosystem with an ever-growing global community. BioVox is a non-profit project: we are able to provide our community with free, quality content because of the generous support of Turnstone Communications and its clients. Our articles bring you hidden opportunities and exclusive insights into the latest research and industry trends!

All posts